SEC Form 4Coverage since Jun 8, 2026
$URGN insider trading
Over the last 12 months, UroGen Pharma insiders reported no purchases and 3 sales totaling $893K across SEC Form 4 filings. 67% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $893K 3 events
- Events · 12m
- 3 Form 4 filings, grouped
- Insiders · 12m
- 1 distinct reporters
- 10b5-1 share
- 67% pre-arranged plans
Side
Price · $URGN · 12Mvia TradingView
Top insiders · 12m
Schoenberg MarkChief Medical Officer3× · $893K
All insider trades
3 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 9, 2026 | Schoenberg MarkChief Medical Officer · O | ▼ Sale | 10,000 | $40 | $400K | -7.7% | plan |
| Jun 22, 2026 | Schoenberg MarkChief Medical Officer · O | ▼ Sale | 10,000 | $35.01 | $350K | -7.2% | plan |
| Jun 8, 2026 | Schoenberg MarkChief Medical Officer · O | ▼ Sale | 5,222 | $27.3 | $143K | -3.6% | — |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $URGN feed.